

## Cerecin appoints Mr. Brian Young-Hoon Kim as new Head of Investor Relations

- *Cerecin expands its senior management team with the appointment of Mr. Brian Young-Hoon Kim as Head of Investor Relations*
- *Appointment is part of the Company's strategic expansion into the Korean market following the recent opening of its new office in Seoul*

**Denver, CO, USA and Singapore November 17, 2022**, Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced the appointment of Mr. Brian Young-Hoon Kim as its new Head of Investor Relations with immediate effect. The appointment is part of the company's strategic expansion into the Korean market, with the recent opening of its new office in Seoul. Mr. Kim will oversee the Company's investor relations activities.

Mr. Kim is an experienced senior executive with more than 20 years of experience in investor relations and equity sales in Asia, most recently serving as the Head of Investor Relations at Avellino Lab, a biotechnology precision medicine firm based in the United States. Prior to this, Mr. Kim led the Investor Relations and Public Relations team at ISU ABXIS, a biotechnology company developing a pipeline of therapeutics in Alzheimer's Disease and rare diseases. Earlier in his career, he worked in equity sales for Korean top brokerage houses, including Korea Investment Securities Hong Kong and NH Investment Securities Hong Kong and Singapore, and worked closely with global asset management companies and government funds.

**Commenting on the appointment, Dr Charles Stacey, CEO and President, Cerecin, said,** "We are very pleased to welcome Mr. Kim to our team. This role is a key hire as we execute our financial strategy and build our presence in South Korea and other key Asian markets. He brings a wealth of experience and a strong network of relationships across the investment community. His deep understanding of the biotechnology industry and capital markets will be invaluable as we continue to advance our ongoing clinical development programs in Alzheimer's disease, migraine and epilepsy."

**Mr. Brian Young-Hoon Kim, Head of Investor Relations, Cerecin, said,** "I am excited to join Cerecin as it continues its important work dedicated to helping patients suffering from neurological disease. The company is well supported by high-calibre investors from South Korea and internationally, and I look forward to using my experience to demonstrate Cerecin's innovative approaches to address some of the most pressing unmet medical needs to the rest of the investment community."

Mr. Kim holds a bachelor's degree from Korea University and a Master's in Business Administration from the University of Iowa Tippie College of Business.

### About Cerecin

Cerecin is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of central nervous system diseases. Cerecin's lead compound, CER-0001, is being developed for migraine, Alzheimer's disease and epilepsy. Cerecin's programs leverage its extensive experience in neurology and global drug development. Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY), and Wilmar International Limited (F34.SI), as well as a syndicate of leading institutional investors. By bringing together the deep expertise of its leadership team and

highly innovative programs, Cerecin is becoming a global leader in bioenergetics and neurometabolism.

### **Forward looking statements**

This press release contains “forward-looking statements” under applicable securities laws that are based on the current expectations and beliefs of Cerecin. Such statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. All statements, except for statements of historical fact, are statements that could be deemed forward-looking statements, including but not limited to: (i) sources and availability of third party financing and investments and the projected financial performance of the Company; (ii) the expected development of the Company’s business, projects, drug development programs and joint ventures; (iii) execution of the Company’s vision and growth strategy, including with respect to future growth; and (iv) new developments with respect to the Company’s projects that are currently underway, in development or otherwise under consideration. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Forward-looking statements are not guaranties of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from projections of future performance or any result that may be expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of Cerecin believes are reasonable assumptions, there can be no assurance or guarantee that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Cerecin undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

**For more information visit [www.cerecin.com](http://www.cerecin.com).**

For further information, please contact:

**Emma Thompson / Hannah Crowe / Claudia Lee / Dennis Wong**

[cerecin@spurwingcomms.com](mailto:cerecin@spurwingcomms.com)

© 2022 Cerecin AC-22-966